Form 4: Cytek Biosciences Executive Valerie Barnett Reports Stock Option and RSU Award
SEC Form 4 Filing
Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.
Summary
- Valerie Barnett, Chief Legal Officer of Cytek Biosciences, filed a Form 4 with the SEC.
- The filing reports the grant of employee stock options for 184,210 shares at an exercise price of $7.07, vesting monthly starting April 6, 2024, and expiring on March 6, 2034.
- Barnett also received 123,762 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Cytek Biosciences common stock.
- The RSUs vest over four years, with portions vesting on May 18, August 18, November 18, and March 10 of each year, starting in 2024 and 2025 respectively.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to slightly positive.
Positives
- The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
- The vesting schedules encourage long-term commitment from the Chief Legal Officer.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure of executive compensation in the form of stock options and RSUs, common practice in the biotechnology industry to incentivize and retain key personnel.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation practices in the biotech industry.
- Companies like Illumina, Thermo Fisher Scientific, and Danaher also utilize equity-based compensation to align executive interests with shareholder value.
- The vesting schedules described are typical for such grants, encouraging long-term commitment.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with long-term company performance.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Date of the transaction (grant of stock options and RSUs) |
| 04/06/2024 | First vesting date for the stock options (1/48 of total shares) |
| 05/18/2024 | First vesting date for a portion of the RSUs (2/48 of total shares) |
| 08/18/2024 | Second vesting date for a portion of the RSUs (3/48 of total shares) |
| 11/18/2024 | Third vesting date for a portion of the RSUs (3/48 of total shares) |
| 03/10/2025 | Fourth vesting date for a portion of the RSUs (4/48 of total shares) |
| 03/06/2034 | Expiration date of the stock options |
| 03/08/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.